Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
CA 2508657 C · Owner: Sommen, Francois Maria · Inventors: De Boeck, Benoit Christian Albert Ghislain; Sommen, Francois Maria; Leenaerts, Joseph Elisabeth
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention concerns substituted 1-piperidin-4-yl-4-pyrrolidin-3-ylpiperazine derivatives having neurokinin antagonistic activity in particular , NK1 antagonistic activity a combined NK1/NK3 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity their preparation, compositions , comprising them and their use as a medicine in particular for the treatment , of schizophrenia anxiety, depression, emesis and IBS. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof the , stereochemically isomeric forms thereof the N-oxide form thereof and prodrugs thereof, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 17, 2003 and granted February 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.